https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-inc-completes-name-change-and-announces-new-ticker/ 2014-08-06T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-16th-annual-rodman-renshaw-global-investment-conference-in-new-york-city-september-8-10th-2014/ 2014-09-03T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-inc-provides-its-first-corporate-update-as-a-public-company/ 2014-09-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-announces-the-filing-of-clinical-trial-application-in-canada-for-d-methadone/ 2014-09-10T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-enters-into-agreement-with-memorial-sloan-kettering-to-better-clarify-unique-mechanism-of-action-for-levocap-er/ 2014-09-16T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-inc-appoints-christopher-w-james-as-senior-director-of-clinical-development/ 2014-09-18T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-julie-j-chen-as-director-of-finance-and-operations/ 2014-10-02T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/new-report-initiates-coverage-on-new-public-biopharmaceutical-company-relmada-therapeutics-inc/ 2014-10-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reinforces-balance-sheet-with-15-2-million-from-exercise-of-warrants/ 2014-10-16T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-adds-15-million-in-capital-to-expedite-development-of-pain-treatment-drugs/ 2014-10-29T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-michael-becker-as-senior-vice-president-of-finance-and-corporate-development/ 2014-11-04T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-ld-micro-conference/ 2014-11-24T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-receives-health-canada-clearance-to-commence-first-clinical-study-of-d-methadone/ 2014-12-02T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-nominated-for-buzz-of-bio-contest-at-the-2015-bio-ceo-investor-conference/ 2014-12-03T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-christine-silverstein-as-director-of-investor-relations/ 2014-12-10T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-results-of-annual-shareholders-meeting/ 2014-12-18T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-doses-first-cohort-of-subjects-in-human-clinical-trial-of-d-methadone/ 2014-12-22T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-provide-corporate-update-at-2015-biotech-showcase-in-san-francisco/ 2015-01-06T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-onemedforum-in-san-francisco/ 2015-01-07T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reaches-midway-point-in-dose-escalation-for-phase-one-study-of-novel-nmda-receptor-antagonist-d-methadone/ 2015-01-13T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-11th-annual-noble-financial-capital-markets-equity-conference/ 2015-01-16T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-selects-mepigel-formulations-to-advance-into-clinical-studies/ 2015-02-04T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-17th-annual-bio-ceo-investor-conference/ 2015-02-09T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-filing-of-clinical-trial-application-in-canada-for-novel-oral-formulations-of-buprenorphine/ 2015-02-24T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-roth-capital-partners-27th-annual-growth-stock-conference/ 2015-03-03T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-names-leading-clinicians-and-researchers-in-pain-therapy-development-to-advisory-roles/ 2015-03-05T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/c-o-r-r-e-c-t-i-o-n-relmada-therapeutics-inc/ 2015-03-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-future-leaders-in-the-biotech-industry-conference/ 2015-03-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-positive-phase-1-results-for-nmda-receptor-antagonist-d-methadone/ 2015-03-17T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-receives-health-canada-clearance-to-commence-first-clinical-study-for-novel-oral-formulations-of-buprenorphine/ 2015-03-24T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-set-for-busy-2015-in-clinical-trials-developing-drugs-for-the-lucrative-pain-market/ 2015-04-02T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-lisa-nolan-ph-d-as-senior-vice-president-of-business-development/ 2015-04-08T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-receives-health-canada-clearance-to-further-explore-promising-nmda-receptor-antagonist-d-methadone-rel-1017/ 2015-04-16T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-commences-proof-of-concept-clinical-study-for-novel-oral-formulations-of-buprenorphine/ 2015-04-21T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-notice-of-allowance-for-u-s-patent-covering-secureltm-its-abuse-deterrent-extended-release-technology-platform-for-opioids/ 2015-05-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-2015-marcum-microcap-conference/ 2015-05-19T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-2015-ld-micro-invitational-conference/ 2015-05-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-successfully-completes-phase-1-single-ascending-dose-study-with-promising-nmda-receptor-antagonist-d-methadone/ 2015-06-10T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-2015-bio-international-convention/ 2015-06-15T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/enrollment-in-relmada-therapeutics-proof-of-concept-clinical-study-for-novel-oral-formulations-of-buprenorphine-reaches-halfway-mark/ 2015-06-29T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-charles-j-casamento-to-its-board-of-directors/ 2015-07-16T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-filing-of-clinical-trial-application-in-canada-for-multiple-ascending-dose-study-with-promising-nmda-receptor-antagonist-d-methadone/ 2015-07-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-reverse-stock-split-in-preparation-for-proposed-uplisting-to-nasdaq-capital-market-2/ 2015-08-10T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-launch-of-new-website-and-corporate-communication-channels/ 2015-08-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-receives-health-canada-clearance-to-commence-multiple-ascending-dose-study-with-promising-nmda-receptor-antagonist/ 2015-08-17T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-two-upcoming-investor-conferences/ 2015-09-02T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-issuance-of-u-s-patent-covering-securel-an-abuse-deterrent-extended-release-technology-platform-for-opioids/ 2015-09-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-ladenburg-thalmann-2015-healthcare-conference/ 2015-09-23T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-aegis-2015-growth-conference/ 2015-10-02T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-management-promotions/ 2015-10-05T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-14th-annual-bio-investor-forum/ 2015-10-13T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-responds-to-13d-filing-by-laidlaw/ 2015-11-05T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-strengthens-its-board-of-directors-with-the-appointment-of-maged-shenouda-and-paul-kelly/ 2015-11-12T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-ld-micro-main-event/ 2015-12-01T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-mail-letter-to-stockholders-highlighting-laidlaw-companys-questionable-business-practices-and-conduct/ 2015-12-07T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-positive-topline-results-for-proof-of-concept-study-with-butab/ 2015-12-09T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-files-federal-lawsuit-against-laidlaw-company-and-its-principals-matthew-eitner-and-james-ahern-to-protect-interests-of-relmada-stockholders/ 2015-12-09T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-additional-information-regarding-positive-topline-results-for-proof-of-concept-study-with-butab/ 2015-12-10T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/u-s-federal-court-issues-temporary-restraining-order-against-laidlaw-company-and-its-principals-matthew-eitner-and-james-ahern/ 2015-12-11T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/pharmaceutical-industry-leader-james-dolan-joins-relmada-therapeutics-advisory-team/ 2015-12-14T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/leading-independent-proxy-advisory-firm-glass-lewis-recommends-relmada-stockholders-vote-the-white-proxy-card-for-relmadas-director-nominees-shreeram-agharkar-and-maged-shenouda/ 2015-12-15T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-sends-letter-to-stockholders-highlighting-significant-progress-in-value-creation-strategy-overseen-by-board-and-management-team/ 2015-12-21T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/u-s-federal-court-grants-preliminary-injunction-against-laidlaw-company-and-its-principals-matthew-eitner-and-james-ahern/ 2015-12-23T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-recommends-stockholders-vote-for-relmadas-director-nominees-on-the-white-proxy-card-today/ 2015-12-28T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-results-of-annual-meeting-of-stockholders/ 2015-12-30T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-successfully-completes-multiple-ascending-dose-study-of-d-methadone-for-neuropathic-pain/ 2016-01-04T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-selected-to-present-at-2016-biotech-showcase-in-san-francisco/ 2016-01-11T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-files-amended-complaint-against-laidlaw-and-its-principals-matthew-eitner-and-james-ahern-2/ 2016-01-26T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-18th-annual-bio-ceo-investor-conference/ 2016-02-02T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-publication-of-full-results-from-phase-i-study-showing-treatment-with-d-methadone-to-be-safe-and-well-tolerated/ 2016-03-01T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-28th-annual-roth-conference/ 2016-03-08T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-inc-provides-update-on-nasdaq-up-listing-process/ 2016-04-14T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-showcase-breadth-of-pipeline-at-upcoming-rd-day/ 2016-04-20T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-additional-details-regarding-upcoming-rd-day/ 2016-04-26T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-joseph-gunnar-pioneers-2016-conference/ 2016-04-28T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-results-of-in-vivo-study-showing-d-methadone-has-antidepressant-like-effects/ 2016-05-04T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-promotion-of-michael-d-becker-to-chief-financial-officer/ 2016-05-16T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-5th-annual-marcum-microcap-conference/ 2016-05-26T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-ld-micro-invitational-conference/ 2016-06-01T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-d-methadone-receives-orphan-drug-designation-for-management-of-postherpetic-neuralgia/ 2016-06-07T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-notice-of-allowance-for-u-s-patent-covering-d-methadone-an-nmda-receptor-antagonist-for-the-treatment-of-depression/ 2016-06-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-secures-first-european-patent-covering-levocap-er/ 2016-07-06T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-rodman-renshaw-18th-annual-global-investment-conference/ 2016-09-07T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/pharmaceutical-industry-leader-ronald-m-burch-joins-relmada-therapeutics-advisory-team/ 2016-09-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-files-amended-complaint-against-laidlaw-and-its-principals-matthew-eitner-and-james-ahern/ 2016-09-14T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-2016-aegis-growth-conference/ 2016-09-20T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-ladenburg-thalmann-2016-healthcare-conference/ 2016-09-22T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-chief-scientific-officer-dr-richard-mangano-to-speak-about-d-methadone-as-a-potential-rapid-acting-antidepressant-at-neuro-advance-boston/ 2016-09-28T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-15th-annual-bio-investor-forum/ 2016-10-06T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-issuance-of-key-u-s-patent-covering-d-methadone-an-nmda-receptor-antagonist-for-the-treatment-of-depression-and-other-psychiatric-symptoms/ 2016-10-19T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-sidoti-company-fall-2016-emerging-growth-convention/ 2016-10-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-ld-micro-main-event-investor-conference/ 2016-11-29T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-biotech-showcase-2017/ 2017-01-05T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-provide-an-update-on-the-development-plan-for-levocap-er/ 2017-01-24T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-announces-fda-acceptance-of-ind-and-authorization-to-commence-phase-2a-clinical-trial-for-d-methadone/ 2017-01-25T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-bio-ceo-and-investor-conference/ 2017-02-13T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-2nd-annual-disruptive-growth-healthcare-conference/ 2017-02-15T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-announces-fda-fast-track-designation-for-d-methadone-for-adjunctive-treatment-of-major-depressive-disorder/ 2017-04-13T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-settlement-of-legal-action-with-laidlaw-company/ 2017-05-18T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/charles-j-casamento-appointed-chairman-of-relmada-therapeutics-board-of-directors/ 2017-06-15T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/dr-ottavio-vitolo-appointed-executive-clinical-advisor-at-relmada-therapeutics/ 2017-06-21T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-dr-maurizio-fava-as-chair-of-the-dextromethadone-scientific-advisory-board-for-its-depression-program/ 2017-06-28T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-6-9-million-private-placement/ 2017-10-05T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-notice-of-acceptance-of-key-patent-in-australia-covering-nmda-receptor-antagonist-d-methadone-for-treatment-of-psychiatric-symptoms/ 2017-10-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-notice-of-acceptance-of-key-patent-in-europe-covering-nmda-receptor-antagonist-d-methadone-for-treatment-of-psychiatric-symptoms/ 2018-01-09T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-acquires-global-rights-to-develop-and-market-dextromethadone-for-treatment-of-disorders-of-the-nervous-system/ 2018-01-17T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/dr-ottavio-vitolo-joins-relmada-therapeutics-as-senior-vice-president-head-of-rd-and-chief-medical-officer/ 2018-04-03T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-inc-announces-first-patient-dosed-in-phase-2-study-of-rel-1017-in-patients-with-major-depressive-disorder/ 2018-06-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-allowed-patent-application-in-china-covering-nmda-receptor-antagonist-d-methadone-for-treatment-of-psychiatric-symptoms/ 2018-08-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-enrollment-update-in-phase-2-study-of-rel-1017-in-patients-with-major-depressive-disorder/ 2018-09-18T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-clinical-data-on-the-effect-of-rel-1017-on-bdnf-plasma-levels/ 2018-10-02T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-presents-clinical-data-on-increased-bdnf-plasma-levels-in-subjects-treated-with-rel-1017/ 2018-12-12T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-biotech-showcase-2019/ 2019-01-02T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/gina-diguglielmo-joins-relmada-as-vice-president-and-head-of-clinical-operations/ 2019-04-03T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-publication-of-rel1017-phase-1-studies-results/ 2019-04-16T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-presents-development-program-of-rel1017-for-treatment-of-depression-at-the-2019-american-society-of-clinical-psychopharmacology-meeting/ 2019-05-31T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-ld-micro-invitational-conference-in-los-angeles/ 2019-06-03T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-completion-of-dosing-with-rel-1017-in-phase-2-study-of-individuals-with-treatment-resistant-depression/ 2019-07-29T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-reverse-stock-split-in-preparation-for-proposed-uplisting-to-nasdaq-capital-market/ 2019-09-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-uplisting-to-the-nasdaq-capital-market/ 2019-10-08T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-commencement-of-trading-on-the-nasdaq-capital-market/ 2019-10-10T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-announce-results-of-phase-2-study-of-rel-1017-for-treatment-resistant-depression-and-conduct-conference-call-on-tuesday-october-15/ 2019-10-14T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-top-line-results-from-rel-1017-phase-2-study-in-individuals-with-treatment-resistant-depression/ 2019-10-15T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-to-ring-nasdaq-stock-market-opening-bell-on-friday-october-18/ 2019-10-17T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-pricing-of-public-offering-of-common-stock/ 2019-12-03T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-proposed-public-offering-of-common-stock-2/ 2019-12-03T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-closing-of-115-million-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares/ 2019-12-09T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-strengthens-board-of-directors-with-appointments-of-life-sciences-industry-veterans-eric-schmidt-ph-d-and-john-glasspool/ 2019-12-20T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-strengthens-financial-operations-with-addition-of-maged-shenouda-as-chief-financial-officer/ 2020-01-10T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-9th-annual-svb-leerink-global-healthcare-conference/ 2020-02-25T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-cns-specialist-thomas-c-wessel-m-d-ph-d-as-executive-vice-president-head-of-research-and-development/ 2020-03-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-strengthens-scientific-leadership-team-with-the-appointment-of-judy-caron-ph-d-as-vice-president-of-drug-development/ 2020-03-24T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-solidifies-its-rd-leadership-team-with-the-appointment-of-marc-de-somer-md-mba-scd-mph-msc-as-senior-vice-president-clinical-development-and-safety/ 2020-03-31T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-enhances-senior-leadership-team-with-appointment-of-brian-a-walter-ph-d-as-vice-president-of-regulatory-affairs/ 2020-04-28T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-molly-harper-as-executive-vice-president-of-operations/ 2020-05-26T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-outcome-of-end-of-phase-2-meeting-with-fda-for-rel-1017-for-adjunctive-treatment-of-patients-with-major-depressive-disorder/ 2020-05-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-jefferies-2020-virtual-healthcare-conference/ 2020-05-29T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference/ 2020-06-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-notice-of-allowance-for-patent-in-canada-covering-rel-1017-for-treatment-of-psychiatric-symptoms/ 2020-06-23T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-uplisting-to-the-nasdaq-global-select-market/ 2020-07-13T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-expands-rd-team-appoints-paolo-manfredi-m-d-as-acting-chief-scientific-officer-marco-pappagallo-m-d-as-acting-chief-medical-officer-and-updates-rd-milestones/ 2020-10-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-upcoming-investor-conferences/ 2020-11-17T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-initiation-of-phase-3-program-for-rel-1017-as-adjunctive-treatment-for-patients-with-major-depressive-disorder/ 2020-12-07T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-participation-in-the-2021-svb-leerink-global-healthcare-conference/ 2021-02-23T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-participation-in-the-oppenheimer-31st-annual-healthcare-conference/ 2021-03-11T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-and-host-conference-call-and-webcast-on-march-23-2021/ 2021-03-18T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2020-financial-results/ 2021-03-23T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-initiation-of-second-pivotal-phase-3-study-of-rel-1017-as-adjunctive-treatment-for-patients-with-major-depressive-disorder/ 2021-04-01T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-poster-presentation-at-the-american-society-for-pharmacology-and-experimental-therapeutics-annual-meeting-at-experimental-biology-2021/ 2021-04-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-participation-in-the-7th-annual-truist-securities-life-sciences-summit/ 2021-04-28T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting/ 2021-04-29T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-poster-presentations-at-the-american-psychiatric-association-annual-meeting-2021/ 2021-05-01T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-first-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-may-12-2021/ 2021-05-06T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2021-financial-results/ 2021-05-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-oral-poster-presentation-on-rel-1017-at-2021-american-society-of-clinical-psychopharmacology-annual-meeting/ 2021-05-26T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-participation-in-jefferies-virtual-healthcare-conference/ 2021-06-01T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-participation-in-goldman-sachs-42nd-annual-global-healthcare-conference/ 2021-06-07T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-data-at-the-college-on-problems-of-drug-dependence-83rd-annual-scientific-meeting/ 2021-06-15T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc/ 2021-07-20T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-top-line-results-of-study-evaluating-rel-1017-vs-oxycodone-for-abuse-potential/ 2021-07-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-second-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-august-10-2021/ 2021-08-05T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-second-quarter-2021-financial-results/ 2021-08-10T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-conference/ 2021-09-03T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-oppenheimer-fall-healthcare-life-sciences-and-medtech-summit/ 2021-09-17T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-regulatory-and-development-updates-on-ongoing-late-stage-clinical-program-for-rel-1017-for-treatment-of-major-depressive-disorder/ 2021-10-04T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-data-at-the-neuroscience-education-institute-congress/ 2021-10-29T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-third-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-november-11-2021/ 2021-11-04T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-jefferies-london-healthcare-conference/ 2021-11-09T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-third-quarter-2021-financial-results/ 2021-11-11T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-data-at-the-60th-annual-meeting-of-the-american-college-of-neuropsychopharmacology/ 2021-12-01T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock/ 2021-12-08T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-proposed-public-offering-of-common-stock/ 2021-12-08T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-closing-of-public-offering-and-full-exercise-of-over-allotment-option/ 2021-12-14T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-publication-of-rel-1017-phase-2-study-results-in-the-american-journal-of-psychiatry/ 2021-12-22T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference/ 2022-02-10T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-top-line-results-of-study-evaluating-rel-1017-vs-ketamine-for-abuse-potential/ 2022-02-23T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-fireside-chats-at-two-upcoming-healthcare-events/ 2022-03-10T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-conference-call-and-webcast-on-march-23-2022/ 2022-03-16T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2021-financial-results/ 2022-03-23T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-data-at-the-ketamine-related-compounds-international-hybrid-conference-2022/ 2022-04-04T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-first-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-may-5-2022/ 2022-04-28T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-publication-of-rel-1017-preclinical-data-in-frontiers-in-pharmacology/ 2022-04-29T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2022-financial-results/ 2022-05-05T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-data-at-the-american-society-of-clinical-psychopharmacology-2022-annual-meeting/ 2022-05-25T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-2022-jefferies-global-healthcare-conference/ 2022-06-02T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-goldman-sachs-43rd-annual-global-healthcare-conference/ 2022-06-07T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-biopharmaceutical-marketing-and-commercial-planning-veteran-john-hixon-as-head-of-commercial/ 2022-07-21T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-second-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-august-11-2022/ 2022-08-05T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-receives-fda-fast-track-designation-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder/ 2022-08-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-second-quarter-2022-financial-results/ 2022-08-11T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-completion-of-treatment-in-companys-registrational-phase-3-reliance-iii-trial-for-rel-1017-as-a-monotherapy-for-major-depressive-disorder/ 2022-09-20T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-top-line-results-from-phase-3-reliance-iii-trial-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder/ 2022-10-13T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-third-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-november-10-2022/ 2022-11-08T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-third-quarter-2022-financial-results/ 2022-11-10T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-top-line-results-from-phase-3-reliance-i-trial-for-rel-1017-as-an-adjunctive-treatment-for-major-depressive-disorder/ 2022-12-07T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-cns-therapeutic-expert-cedric-ogorman-md-as-chief-medical-officer/ 2023-01-09T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-fabiana-fedeli-from-mg-investments-to-its-board-of-directors/ 2023-01-12T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-and-webcast-on-march-23-2023/ 2023-03-17T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022-financial-results/ 2023-03-23T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-first-quarter-2023-financial-results-and-host-conference-call-and-webcast-on-may-11-2023/ 2023-05-08T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2023-financial-results/ 2023-05-11T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-data-at-the-american-society-of-clinical-psychopharmacology-2023-annual-meeting/ 2023-05-24T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-2023-jefferies-global-healthcare-conference/ 2023-06-02T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-goldman-sachs-global-healthcare-conference/ 2023-06-08T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-second-quarter-2023-financial-results-and-host-conference-call-and-webcast-on-august-8-2023/ 2023-08-01T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-second-quarter-2023-financial-results/ 2023-08-08T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-dosing-of-first-patient-in-relight-a-phase-3-trial-of-rel-1017-for-the-adjunctive-treatment-of-major-depressive-disorder/ 2023-08-23T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-efficacy-and-safety-results-from-the-phase-3-long-term-study-of-rel-1017-in-major-depressive-disorder/ 2023-09-20T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-data-from-its-rel-1017-and-psilocybin-programs-at-the-36th-european-college-of-neuropsychopharmacology-ecnp-congress/ 2023-10-06T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-jefferies-inaugural-biotech-cns-neuro-summit/ 2023-10-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-new-preclinical-data-on-its-psilocybin-program-at-aasld-the-liver-meeting-2023/ 2023-10-11T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-third-quarter-2023-financial-results-and-host-conference-call-and-webcast-on-november-8-2023/ 2023-11-03T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-third-quarter-2023-financial-results/ 2023-11-08T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update/ 2024-01-04T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-leerink-partners-global-biopharma-conference/ 2024-03-05T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-conference-call-and-webcast-on-march-19-2024/ 2024-03-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2023-financial-results/ 2024-03-19T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-first-quarter-2024-financial-results-and-host-conference-call-and-webcast-on-may-8-2024/ 2024-05-06T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-results/ 2024-05-08T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-2024-jefferies-global-healthcare-conference/ 2024-06-03T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference/ 2024-06-10T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announced-publication-of-results-from-the-phase-3-reliance-i-study-of-rel-1017-in-the-journal-of-clinical-psychiatry/ 2024-06-18T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-second-quarter-2024-financial-results-on-august-7-2024/ 2024-08-05T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-update/ 2024-08-07T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-third-quarter-2024-financial-results-on-november-7-2024/ 2024-11-04T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update/ 2024-11-07T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-initiates-phase-1-dosing-with-rel-p11-for-metabolic-disease/ 2024-11-14T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-jefferies-london-healthcare-conference/ 2024-11-19T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-that-data-monitoring-committee-dmc-assessment-indicates-that-the-phase-3-reliance-ii-trial-is-futile-at-its-interim-analysis-and-is-unlikely-to-meet-the-primary-efficacy/ 2024-12-04T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-discontinue-the-reliance-ii-and-relight-phase-3-studies-of-rel-1017/ 2024-12-09T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-acquires-potential-therapy-for-tourette-syndrome-from-asarina-pharma-ab/ 2025-02-06T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-licenses-phase-2-bladder-cancer-candidate-ndv-01-from-trigone-pharma-ltd/ 2025-03-25T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-fourth-quarter-2024-financial-results-on-thursday-march-27-2025/ 2025-03-26T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-fourth-quarter-and-full-year-2024-results-and-provides-business-update/ 2025-03-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/update-relmada-therapeutics-to-present-ndv-01-data-at-aua2025-2/ 2025-04-14T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-ndv-01-data-at-aua2025/ 2025-04-14T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-host-kol-event-on-phase-2-ndv-01-data/ 2025-04-24T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/update-relmada-therapeutics-to-present-ndv-01-data-at-aua2025/ 2025-04-27T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-presents-positive-initial-phase-2-ndv-01-data-at-aua2025/ 2025-04-28T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025/ 2025-05-08T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update/ 2025-05-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-urology-expert-raj-s-pruthi-md-as-cmo-urology/ 2025-06-17T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-renowned-urologic-oncologist-yair-lotan-md-to-chair-the-clinical-advisory-board-and-support-development-of-ndv-01/ 2025-07-15T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-second-quarter-2025-financial-results-on-thursday-august-7-2025/ 2025-07-31T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-second-quarter-2025-financial-results-and-announces-ndv-01-6-month-follow-up-safety-and-efficacy-data-in-nmibc/ 2025-08-07T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-issues-mid-year-ceo-letter-to-shareholders/ 2025-09-10T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-regains-compliance-with-nasdaq-minimum-bid-price-requirement/ 2025-09-16T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-distinguished-urologic-oncologist-max-kates-md-to-the-clinical-advisory-board-to-support-development-of-ndv-01/ 2025-10-07T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-pricing-of-100-million-underwritten-offering-of-common-stock-and-pre-funded-warrants/ 2025-11-04T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-announces-fda-feedback-supporting-2-separate-acceptable-registrational-study-paths-for-ndv-01-in-non-muscle-invasive-bladder-cancer/ 2025-11-04T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-third-quarter-2025-financial-results-on-thursday-november-13-2025/ 2025-11-07T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-third-quarter-2025-financial-results-and-provides-key-clinical-regulatory-and-corporate-updates/ 2025-11-13T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-presentation-of-ndv-01-phase-2-data-at-the-society-for-urologic-oncology/ 2025-12-03T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-provides-regulatory-update-confirming-fda-alignment-on-registrational-studies-design-for-ndv-01-for-two-separate-indications/ 2026-01-12T05:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conference/ 2026-03-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-announces-oversubscribed-160-0-million-private-placement-financing/ 2026-03-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-12-month-phase-2-interim-data-for-ndv-01-in-non-muscle-invasive-bladder-cancer/ 2026-03-09T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-fourth-quarter-2025-financial-results-on-thursday-march-19-2026-2/ 2026-03-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-fourth-quarter-and-full-year-2025-results-and-provides-business-update-2/ 2026-03-19T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-ndv-01-abstracts-at-aua2026-2/ 2026-05-05T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-first-quarter-2026-financial-results-on-tuesday-may-12-2026-2/ 2026-05-06T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update-2/ 2026-05-12T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2/ 2026-05-28T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-senior-advisor-for-sepranolone-program/ 2026-06-11T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-joins-russell-2000-and-russell-3000-indexes/ 2026-06-29T04:00:00+00:00 https://relmada.lifescicreative.com/press_releases/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-august-6-2026/ 2026-07-17T11:21:53+00:00